Conversely, inhibition of activin A or ActRII improves cardiac function and remodeling in multiple animal models of HF, including TAC, LAD ligation, aging, cancer, dilated cardiomyopathy, and PPCM[84,161,166–168]. This evidence concerns the gene ACVR2A and hydrops fetalis.